ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: Pasireotide Works Well In Acromegaly Trial

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the company said Monday. Patients treated with pasireotide LAR, or SOM230, were 63% more likely to achieve control of their disease than those treated with Novartis' Sandostatin LAR, or octreotide, the study showed. The safety profile of pasireotide LAR was similar to that of octreotide LAR, known under the brand name Sandostatin, with the exception of a higher degree of hyperglycemia, Novartis said. "The positive results seen in the Phase III trial point to the potential role of pasireotide LAR in treating patients with acromegaly, a condition for which there remains an unmet need," said Herve Hoppenot, president of Novartis Oncology, in a statement. "These findings are welcome news as we continue our research efforts to discover treatments for patients with pituitary-related conditions." Acromegaly, a rare endocrine disorder caused by excess growth hormone, can result in enlarged hands, feet and internal organs, and increased risk of death. Novartis said the data were presented at the 15th International Congress of Endocrinology and 14th European Congress of Endocrinology meeting in Florence, Italy. The medical meeting runs from May 5 to May 9. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
02/09/201613:00:00Novartis Reaches Entresto Pay-for-Performance Deals With Cigna...
02/09/201612:57:00Novartis Reaches Entresto Pay-for-Performance Deals With Cigna...
02/03/201611:04:00Investors' Fears Eased as Glaxo Posts Solid Results -- Update
02/03/201608:30:00GlaxoSmithKline Posts $510 Million Net Loss
02/03/201608:23:00GlaxoSmithKline Posts GBP354 Million Net Loss in 4Q
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/27/201616:30:00Radius Health Announces Clinical Collaboration With a Leading...
01/27/201609:57:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201605:10:00Global Stocks Edge Lower Ahead of U.S. Interest Rate Decision
01/27/201604:44:00Novartis Profit Dives 57% on Eye-Care Woes --2nd Update
01/27/201603:01:00Novartis Net Profit Falls 57% --Update
01/27/201602:50:00Novartis Net Profit Falls 57%
01/27/201602:02:00Novartis 4Q Net Profit Falls 57% as Eye-Care Unit Drags on Results
01/22/201611:53:00CEOs Sanguine on M&A Prospects in Spite of Markets Dive --Update
01/22/201609:06:00Novartis AG 4Q 2015 -- Forecast
01/20/201619:29:00Drug and Diagnostic Companies Issue Joint Declaration on Antibiotics
01/11/201610:10:00Juno Agrees to Acquire AbVitro
12/17/201519:49:00Ligand Pharma to Buy Genetic Engineering Company OMT -- 2nd Update
12/17/201505:10:00Global Stocks Rally After Fed Decision
12/07/201515:53:00U.S. Stocks Fall as Oil Keeps Sliding

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad